119 related articles for article (PubMed ID: 36052502)
21. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.
van Soest RJ; de Morrée ES; Kweldam CF; de Ridder CMA; Wiemer EAC; Mathijssen RHJ; de Wit R; van Weerden WM
Eur Urol; 2015 Jun; 67(6):981-985. PubMed ID: 25484141
[TBL] [Abstract][Full Text] [Related]
22. Emerging mechanisms of enzalutamide resistance in prostate cancer.
Claessens F; Helsen C; Prekovic S; Van den Broeck T; Spans L; Van Poppel H; Joniau S
Nat Rev Urol; 2014 Dec; 11(12):712-6. PubMed ID: 25224448
[TBL] [Abstract][Full Text] [Related]
23. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
24. GSTM2 is a key molecular determinant of resistance to SG-ARIs.
Li C; Liu J; He D; Mao F; Rao X; Zhao Y; Lanman NA; Kazemian M; Farah E; Liu J; Ngule CM; Zhang Z; Zhang Y; Kong Y; Li L; Wang C; Liu X
Oncogene; 2022 Sep; 41(40):4498-4511. PubMed ID: 36038661
[TBL] [Abstract][Full Text] [Related]
25. Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer.
Buttigliero C; Tucci M; Bertaglia V; Vignani F; Bironzo P; Di Maio M; Scagliotti GV
Cancer Treat Rev; 2015 Dec; 41(10):884-92. PubMed ID: 26342718
[TBL] [Abstract][Full Text] [Related]
26. A novel androgen receptor antagonist JJ-450 inhibits enzalutamide-resistant mutant AR
Wu Z; Wang K; Yang Z; Pascal LE; Nelson JB; Takubo K; Wipf P; Wang Z
Prostate; 2020 Mar; 80(4):319-328. PubMed ID: 31868960
[TBL] [Abstract][Full Text] [Related]
27. Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
Tang D; He J; Dai Y; Geng X; Leng Q; Jiang H; Sun R; Xu S
Cancer Gene Ther; 2022 May; 29(5):543-557. PubMed ID: 33854217
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor splice variants in the era of enzalutamide and abiraterone.
Nakazawa M; Antonarakis ES; Luo J
Horm Cancer; 2014 Oct; 5(5):265-73. PubMed ID: 25048254
[TBL] [Abstract][Full Text] [Related]
29. SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway.
Du Z; Chen X; Zhu P; Sun W; Lv Q; Cheng S; Yang X; Yu X
Biomed Res Int; 2022; 2022():9235837. PubMed ID: 36246971
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X
J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652
[TBL] [Abstract][Full Text] [Related]
31. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor aberrations in the era of abiraterone and enzalutamide.
Jentzmik F; Azoitei A; Zengerling F; Damjanoski I; Cronauer MV
World J Urol; 2016 Mar; 34(3):297-303. PubMed ID: 26100946
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis.
Han H; Wang Y; Curto J; Gurrapu S; Laudato S; Rumandla A; Chakraborty G; Wang X; Chen H; Jiang Y; Kumar D; Caggiano EG; Capogiri M; Zhang B; Ji Y; Maity SN; Hu M; Bai S; Aparicio AM; Efstathiou E; Logothetis CJ; Navin N; Navone NM; Chen Y; Giancotti FG
Cell Rep; 2022 Apr; 39(1):110595. PubMed ID: 35385726
[TBL] [Abstract][Full Text] [Related]
35. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
36. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
Shafi AA; Yen AE; Weigel NL
Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
[TBL] [Abstract][Full Text] [Related]
37. An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma.
Li L; Chen D; Chen X; Zhu J; Bao W; Li C; Miao F; Feng R
PeerJ; 2024; 12():e16850. PubMed ID: 38562999
[TBL] [Abstract][Full Text] [Related]
38. Metabolic Reprogramming and Predominance of Solute Carrier Genes during Acquired Enzalutamide Resistance in Prostate Cancer.
Verma S; Shankar E; Chan ER; Gupta S
Cells; 2020 Nov; 9(12):. PubMed ID: 33255236
[TBL] [Abstract][Full Text] [Related]
39. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer.
Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D
Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
